Literature DB >> 7472547

Late patency of long saphenous vein bypass grafts to the anterior and posterior cerebral circulation.

L Regli1, D G Piepgras, K K Hansen.   

Abstract

To evaluate the late results and the natural history of long saphenous vein bypass grafts (SVGs) between the extracranial and intracranial circulation, the authors retrospectively analyzed 202 consecutive SVGs performed at the Mayo Clinic from 1979 to 1992. The distal anastomosis was to the vertebrobasilar system in 98 patients and to the carotid artery system in 103 patients. Surgical indications were advanced cerebroocclusive disease in 63% (127 cases), giant aneurysm in 37% (74 cases), and neoplasm in one patient. In 125 patent SVGs follow-up information was obtained for longer than 1 year and in 23 patent SVGs it was over 10 years (maximum 13 years, median 6.5 years). Most of the graft failures (76%) occurred during the 1st year after surgery, with 42% of all graft failures found during the first 24 hours after operation. Late graft attrition occurred in only 10 patients (8%). Cumulative patency at 1 year was 86% +/- 3%, at 5 years 82% +/- 4%, and at 13 years 73% +/- 19%. Neurological worsening at the time of occlusion developed in 72% of patients with early occlusion, whereas 80% of patients with late graft occlusion had no new neurological symptoms. Long-term patency of SVGs for cerebral revascularization appears to be excellent, with an average failure rate of 1% to 1.5% per year following the 1st year after surgery. To minimize early graft thrombosis, meticulous attention must be paid to technical detail.

Entities:  

Mesh:

Year:  1995        PMID: 7472547     DOI: 10.3171/jns.1995.83.5.0806

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  16 in total

1.  Stent graft placement for the treatment of giant aneurysm at the proximal cavernous internal carotid artery. A case report.

Authors:  S Katayama; K Fujita; N Takeda; Y Okamura
Journal:  Interv Neuroradiol       Date:  2006-06-15       Impact factor: 1.610

2.  Management of complex intracranial aneurysms with bypass surgery: a technique application and experience in 93 patients.

Authors:  Xiangen Shi; Hai Qian; Tie Fang; Yongli Zhang; Yuming Sun; Fangjun Liu
Journal:  Neurosurg Rev       Date:  2014-08-26       Impact factor: 3.042

3.  Revascularization of the posterior circulation.

Authors:  Bert A Coert; Steven D Chang; Michael P Marks; Gary K Steinberg
Journal:  Skull Base       Date:  2005-02

4.  Revascularization for complex skull base tumors.

Authors:  Jorge Mura; David Rojas-Zalazar; Evandro de Oliveira
Journal:  Skull Base       Date:  2005-02

5.  Diagnosis and neurosurgical treatment of intracranial vascular occlusive syndromes.

Authors:  Sepideh Amin-Hanjani
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-06

6.  Thrombectomy for late occlusion of high flow extracranial-intracranial saphenous vein bypass graft after 27 years of patency.

Authors:  Michael A Silva; Rodolfo E Alcedo Guardia; Mohammad Ali Aziz-Sultan; Nirav J Patel
Journal:  BMJ Case Rep       Date:  2018-03-08

7.  Revascularization with saphenous vein bypasses for complex intracranial aneurysms.

Authors:  Alfredo Quiñones-Hinojosa; Rose Du; Michael T Lawton
Journal:  Skull Base       Date:  2005-05

8.  Intracranial aneurysms in adolescents.

Authors:  Jian-tao Liang; Li-rong Huo; Yu-hai Bao; Hong-qi Zhang; Zhen-yu Wang; Feng Ling
Journal:  Childs Nerv Syst       Date:  2011-01-06       Impact factor: 1.475

Review 9.  Extracranial-intracranial arterial bypass for treatment of occlusion of the internal carotid artery.

Authors:  Robert L Grubb
Journal:  Curr Neurol Neurosci Rep       Date:  2004-01       Impact factor: 5.081

10.  Symptomatic cavernous sinus aneurysms: management and outcome after carotid occlusion and selective cerebral revascularization.

Authors:  Melvin Field; Charles A Jungreis; Nicole Chengelis; Holly Kromer; Lori Kirby; Howard Yonas
Journal:  AJNR Am J Neuroradiol       Date:  2003 Jun-Jul       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.